Peptide · Visceral fat
Tesamorelin: the FDA-approved visceral fat peptide
Tesamorelin is the only GHRH analog with FDA approval — originally for HIV-associated visceral fat accumulation. In clinical trials, it reduced deep abdominal fat by 15–20% over 6 months. That's why it's increasingly discussed for postmenopausal belly fat.
Why the visceral fat angle matters in menopause
After menopause, subcutaneous fat proportion drops and visceral fat proportion rises — even at stable body weight. Visceral fat drives insulin resistance, cardiovascular risk, and inflammatory aging. A therapy that selectively reduces visceral fat has a different value than one that just lowers the scale number.
The pivotal trials
Two phase-3 trials (Falutz et al., NEJM 2007) enrolled 816 patients with HIV lipodystrophy. After 26 weeks of 2 mg daily tesamorelin, VAT decreased by ~18% vs a 2% increase in placebo. Triglycerides fell 50 mg/dL. IGF-1 rose into the upper-normal range.
How it's used off-label in longevity practice
Physician-supervised protocols typically use 1–2 mg subcutaneous daily for 12–26 weeks, with IGF-1 monitored monthly. Effects on visceral fat plateau around month 6.
Frequently asked questions
Is tesamorelin FDA-approved?
Yes — for HIV-associated lipodystrophy under the brand Egrifta. Use for postmenopausal visceral fat is off-label.
How much visceral fat does tesamorelin remove?
Pivotal trials showed a 15–20% reduction in visceral adipose tissue (VAT) on MRI over 26 weeks at 2 mg subcutaneous daily.
Tesamorelin vs sermorelin?
Both are GHRH analogs. Tesamorelin has a longer half-life and stronger data on visceral fat reduction. Sermorelin is cheaper and more widely available.
Does tesamorelin cause weight loss on the scale?
Not much. It preferentially removes visceral fat and preserves lean mass, so total scale weight often changes very little — but waist circumference and metabolic markers improve.
Is tesamorelin safe for postmenopausal women?
Not studied in menopause-specific trials. Standard GH-axis contraindications apply: active cancer, pregnancy, diabetic retinopathy.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.